近岸蛋白：公司暂未开展股票回购

Company Overview - Nearshore Protein (SH 688137) announced on August 4 that as of July 31, 2025, the company has not yet initiated a stock buyback, but will consider implementing the buyback plan based on market conditions [1] Financial Performance - For the year 2024, the revenue composition of Nearshore Protein is as follows: - Life Sciences Basic Research: 43.35% - In Vitro Diagnostics: 18.64% - Biopharmaceuticals: 16.2% - Other Businesses: 12.54% - mRNA Vaccine Drugs: 9.27% [1] Market Capitalization - As of the report, the market capitalization of Nearshore Protein is 3.4 billion yuan [1]